J.Molner AS (OTSE:MOLNR) Interest Coverage: 7.48 (As of Dec. 2025) — 1106% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OTSE:MOLNR J.Molner AS OTSE:MOLNR
40 GF Score
Price €18.90
GF Value €19.62
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is J.Molner AS Interest Coverage?

J.Molner AS OTSE:MOLNR -0.53% 40 Interest Coverage is 7.48 as of Dec. 2025, which is 1106% above its 10-year median of 0.62. GuruFocus rates OTSE:MOLNR with a GF Score™ of 40/100 and a GF Value™ of €19.62 (Fairly Valued). The stock has 7 warning signs investors should review. Among 679 Drug Manufacturers companies, J.Molner AS ranks worse than 95.58% on this metric.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. J.Molner AS's Operating Income for the six months ended in Dec. 2025 was €1.80 Mil. J.Molner AS's Interest Expense for the six months ended in Dec. 2025 was €-0.24 Mil. J.Molner AS's interest coverage for the quarter that ended in Dec. 2025 was 7.48. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for J.Molner AS's Interest Coverage or its related term are showing as below:

OTSE:MOLNR' s Interest Coverage Range Over the Past 10 Years
Min: 0.61   Med: 0.62   Max: 0.62
Current: 0.61


OTSE:MOLNR's Interest Coverage is ranked worse than
95.58% of 679 companies
in the Drug Manufacturers industry
Industry Median: 12.99 vs OTSE:MOLNR: 0.61

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


J.Molner AS  (OTSE:MOLNR) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


J.Molner AS Interest Coverage Related Terms


J.Molner AS Interest Coverage Historical Data

* Premium members only.

The historical data trend for J.Molner AS's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

J.Molner AS Interest Coverage Chart

J.Molner AS Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Interest Coverage
0.00 0.00 0.00 0.00 0.62

J.Molner AS Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Coverage Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 7.48

OTSE:MOLNR vs ZTS, UTHR, VTRS: Interest Coverage Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, J.Molner AS's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


J.Molner AS Interest Coverage vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, J.Molner AS's Interest Coverage distribution charts can be found below:

* The bar in red indicates where J.Molner AS's Interest Coverage falls into.


OTSE:MOLNR
40GF Score
J.Molner AS OTSE:MOLNR
Interest Coverage is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

J.Molner AS Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

J.Molner AS's Interest Coverage for the fiscal year that ended in Dec. 2025 is calculated as

Here, for the fiscal year that ended in Dec. 2025, J.Molner AS's Interest Expense was €-0.48 Mil. Its Operating Income was €0.30 Mil. And its Long-Term Debt & Capital Lease Obligation was €0.74 Mil.

Interest Coverage=-1* Operating Income (A: Dec. 2025 )/Interest Expense (A: Dec. 2025 )
=-1*0.299/-0.483
=0.62

J.Molner AS's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Here, for the six months ended in Dec. 2025, J.Molner AS's Interest Expense was €-0.24 Mil. Its Operating Income was €1.80 Mil. And its Long-Term Debt & Capital Lease Obligation was €0.74 Mil.

Interest Coverage=-1* Operating Income (Q: Dec. 2025 )/Interest Expense (Q: Dec. 2025 )
=-1*1.802/-0.241
=7.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Frequently Asked Questions Learn more about Interest Coverage →
What does a Interest Coverage of 7.48 mean?
J.Molner AS (OTSE:MOLNR) has a Interest Coverage of 7.48 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on J.Molner AS and its competitors. This is 1106% above median its historical median of 0.62. Over the past decade, J.Molner AS's Interest Coverage has ranged from 0.61 to 0.62. According to the industry distribution chart, J.Molner AS ranks #649 out of 679 companies in the Drug Manufacturers industry, placing it in the top 95.6%.
Is J.Molner AS's Interest Coverage too high?
J.Molner AS's current Interest Coverage of 7.48 is 1106% above median its 10-year median of 0.62. Over the past 10 years, this metric has ranged from a low of 0.61 to a high of 0.62. The Drug Manufacturers industry median Interest Coverage is 12.99. J.Molner AS's value of 7.48 is 42.4% below this industry median. Based on the distribution chart, J.Molner AS ranks #649 out of 679 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, J.Molner AS has a GF Score™ of 40/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does J.Molner AS's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, J.Molner AS ranks #649 out of 679 companies for Interest Coverage. This places J.Molner AS in the lower half of its industry. The industry median Interest Coverage is 12.99. J.Molner AS's value of 7.48 is 42.4% below this benchmark. Historically, J.Molner AS's own Interest Coverage has ranged from 0.61 to 0.62 over the past decade. While the company's 10-year median is 0.62 vs. the industry median of 12.99, J.Molner AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.99, based on 679 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. J.Molner AS's current Interest Coverage of 7.48 is 42.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on J.Molner AS and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. J.Molner AS's current Interest Coverage is 7.48, which is 1106% above median its own 10-year median of 0.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is J.Molner AS stock overvalued right now?
Based on GuruFocus' analysis, J.Molner AS (OTSE:MOLNR) is currently considered Fairly Valued. The stock's GF Value™ is €19.62, compared to a current price of €18.90 — trading 3.7% below its estimated fair value. The current Interest Coverage is 7.48, which is 1106% above median its 10-year median of 0.62 and 42.4% below the Drug Manufacturers industry median of 12.99. J.Molner AS's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For J.Molner AS (OTSE:MOLNR), the current Interest Coverage is 7.48 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is J.Molner AS (OTSE:MOLNR) Overvalued in 2026?

Based on GuruFocus' analysis, J.Molner AS stock appears to be undervalued. The current stock price of €18.90 is trading 3.7% below its estimated GF Value™ of €19.62. GuruFocus considers J.Molner AS to be Fairly Valued.

Key valuation signals for OTSE:MOLNR:

  • Interest Coverage: 7.48 (1106% above median its 10-year median of 0.62)
  • GF Value™: €19.62 vs. price of €18.90 (3.7% below fair value)
  • GF Score™: 40/100 with 7 warning signs
  • Industry Position: 42.4% below the Drug Manufacturers median (#649 of 679)

No single metric tells the full story. See the OTSE:MOLNR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


J.Molner AS Business Description

Address Akadeemia tee 21/5, Harju maakond, Tallinn, EST, 12618
J.Molner AS is an Estonia-based company engaged in research and development in the field of biotechnology. It is developing a portfolio of generic drug products for the United States and Canadian markets, consisting of both in-house developed medicines and acquired and in-licensed products. It operates through two complementary business units: internal generic drug development and specialized pharmaceutical services. It develops and commercializes sterile injectable, ophthalmic, and dermatology generic drugs, while also providing drug development services, analytical chemistry and stability testing. Its activities are divided into two business segments, Generic Drugs and Services, with Services generating maximum revenue. The Company generates maximum revenue from the United States.
40GF Score

Get the complete analysis for OTSE:MOLNR

Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.90
Price
€19.62
GF Value